KR101938431B1 - 뇌 종양의 치료를 위한 csf-1r 억제제 - Google Patents

뇌 종양의 치료를 위한 csf-1r 억제제 Download PDF

Info

Publication number
KR101938431B1
KR101938431B1 KR1020137031960A KR20137031960A KR101938431B1 KR 101938431 B1 KR101938431 B1 KR 101938431B1 KR 1020137031960 A KR1020137031960 A KR 1020137031960A KR 20137031960 A KR20137031960 A KR 20137031960A KR 101938431 B1 KR101938431 B1 KR 101938431B1
Authority
KR
South Korea
Prior art keywords
tumor
csf
blz945
brain
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137031960A
Other languages
English (en)
Korean (ko)
Other versions
KR20140029475A (ko
Inventor
딜런 다니엘
요한나 조이스
제임스 서튼
Original Assignee
노파르티스 아게
슬로안-케테링인스티튜트퍼캔서리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 슬로안-케테링인스티튜트퍼캔서리서치 filed Critical 노파르티스 아게
Publication of KR20140029475A publication Critical patent/KR20140029475A/ko
Application granted granted Critical
Publication of KR101938431B1 publication Critical patent/KR101938431B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137031960A 2011-05-05 2012-05-04 뇌 종양의 치료를 위한 csf-1r 억제제 Expired - Fee Related KR101938431B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161482723P 2011-05-05 2011-05-05
US61/482,723 2011-05-05
US201261624861P 2012-04-16 2012-04-16
US61/624,861 2012-04-16
PCT/US2012/036589 WO2012151523A1 (en) 2011-05-05 2012-05-04 Csf-1r inhibitors for treatment of brain tumors

Publications (2)

Publication Number Publication Date
KR20140029475A KR20140029475A (ko) 2014-03-10
KR101938431B1 true KR101938431B1 (ko) 2019-01-14

Family

ID=46062775

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137031960A Expired - Fee Related KR101938431B1 (ko) 2011-05-05 2012-05-04 뇌 종양의 치료를 위한 csf-1r 억제제

Country Status (19)

Country Link
US (3) US20140065141A1 (enExample)
EP (1) EP2704713B1 (enExample)
JP (1) JP6046702B2 (enExample)
KR (1) KR101938431B1 (enExample)
CN (1) CN103501785B (enExample)
BR (1) BR112013028095B1 (enExample)
CA (1) CA2834696C (enExample)
CY (1) CY1119642T1 (enExample)
DK (1) DK2704713T3 (enExample)
EA (1) EA023999B1 (enExample)
ES (1) ES2622527T3 (enExample)
HR (1) HRP20170593T1 (enExample)
HU (1) HUE032754T2 (enExample)
LT (1) LT2704713T (enExample)
MX (1) MX347616B (enExample)
PL (1) PL2704713T3 (enExample)
PT (1) PT2704713T (enExample)
SI (1) SI2704713T1 (enExample)
WO (1) WO2012151523A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147631A1 (en) * 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
WO2016182988A1 (en) 2015-05-08 2016-11-17 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
MA47395A (fr) * 2015-05-27 2019-12-11 Ucb Biopharma Sprl Méthode pour le traitement d'une maladie neurologique
CN108367070B (zh) 2015-11-04 2022-10-28 杜克大学 免疫毒素与检查点抑制剂的组合治疗
CN109789209A (zh) * 2016-10-14 2019-05-21 诺华股份有限公司 使用csf-1r抑制剂治疗眼部疾病的方法
EP3526217B1 (en) * 2016-10-14 2023-04-19 Novartis AG Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide
MA46716A (fr) 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018223098A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
CA3067602A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US20210071258A1 (en) 2017-09-01 2021-03-11 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
EP3836951A1 (en) 2018-08-13 2021-06-23 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
EP3886894B1 (en) 2018-11-30 2024-03-13 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
CN110468210A (zh) * 2019-09-12 2019-11-19 暨南大学 Cdc45作为胶质母细胞瘤标志物及其作为治疗靶点的应用
WO2021113770A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
EP4214198A4 (en) * 2020-09-21 2024-10-09 Hutchison Medipharma Limited Heteroaromatic compounds and uses thereof
CN115969979B (zh) * 2022-12-30 2025-08-29 中国人民解放军陆军军医大学第一附属医院 C620-0580在制备抗胶质瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100721656B1 (ko) 2005-11-01 2007-05-23 주식회사 엘지화학 유기 전기 소자
CN101466682A (zh) * 2006-04-14 2009-06-24 阿斯利康(瑞典)有限公司 作为csf-1r激酶抑制剂的4-苯胺基喹啉-3-甲酰胺
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
MX2008013427A (es) * 2006-04-19 2008-11-04 Novartis Ag Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8293769B2 (en) * 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use

Also Published As

Publication number Publication date
HUE032754T2 (en) 2017-10-30
PL2704713T3 (pl) 2017-08-31
PT2704713T (pt) 2017-04-24
US20140065141A1 (en) 2014-03-06
WO2012151523A1 (en) 2012-11-08
JP6046702B2 (ja) 2016-12-21
US10537561B2 (en) 2020-01-21
DK2704713T3 (en) 2017-04-24
CA2834696A1 (en) 2012-11-08
JP2014513136A (ja) 2014-05-29
BR112013028095A2 (pt) 2016-12-27
BR112013028095B1 (pt) 2020-03-03
MX2013012939A (es) 2014-02-27
LT2704713T (lt) 2017-04-25
MX347616B (es) 2017-05-04
US20190030013A1 (en) 2019-01-31
US20150306085A1 (en) 2015-10-29
EA201391629A1 (ru) 2016-01-29
CN103501785A (zh) 2014-01-08
AU2012250574A1 (en) 2013-11-28
EP2704713B1 (en) 2017-01-18
SI2704713T1 (sl) 2017-05-31
AU2012250574A8 (en) 2016-07-28
KR20140029475A (ko) 2014-03-10
HRP20170593T1 (hr) 2017-07-14
CN103501785B (zh) 2016-10-26
EP2704713A1 (en) 2014-03-12
EA023999B1 (ru) 2016-08-31
ES2622527T3 (es) 2017-07-06
AU2012250574B2 (en) 2016-07-07
CA2834696C (en) 2019-07-23
CY1119642T1 (el) 2018-04-04

Similar Documents

Publication Publication Date Title
KR101938431B1 (ko) 뇌 종양의 치료를 위한 csf-1r 억제제
US20240316009A1 (en) Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
US20240076271A1 (en) Kdm4 inhibitors
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
WO2012151541A1 (en) Csf-1r inhibitors for treatment of brain tumors
KR101401891B1 (ko) 테모졸로미드 및 발프로산을 함께 이용하는 항암적 용도
US20210137898A1 (en) Methods to treat gliomas using a stat3 inhibitor
AU2012250574B8 (en) CSF-1R inhibitors for treatment of brain tumors
US10213449B2 (en) Compositions and methods for treating medulloblastoma
US20210023107A1 (en) USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
US20220347180A1 (en) Enhancing cancer therapy treatment with bh3 mimetics
Janouskova Role of α5β1 integrin/p53 pathway in the resistance of glioma and colon cancer to therapy
JP2017081861A (ja) グリオーマ治療剤及びその有効性を判定する方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230109

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230109